HIV, HBV and HCV seropositivity in hemophiliacs. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HIV, HBV and HCV seropositivity in hemophiliacs.

Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih. 1991 Nov;24(4):339-44. Unique Identifier : AIDSLINE MED/93314407
Chow MP; Lin CK; Lin JS; Chau WK; Ho CH; Chen SY; Lee SH; Yung CH; Department of Medicine, Veterans General Hospital-Taipei, Taiwan,; Republic of China.

Abstract: Eleven cases of severe type hemophiliacs who had received long-term factor VIII injections were tested for the serological markers of human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus (HCV). The period of factor VIII concentrate injections ranged from 2 to 32 years. The seropositive rates of HIV and HCV were 9/11(82%) and 11/11(100%), respectively. The seropositive rate of hepatitis B surface antigen was only 1/11(9%), while the seropositive rates of antibody to hepatitis B core antigen and antibody to hepatitis B surface antigen were 9/11(82%) and 7/11(64%), respectively, Although the patients had no symptoms related to acquired immunodeficiency syndrome, they were noted to have inverted helper/suppressor T-lymphocyte ratio, suggesting that hemophiliacs with long-term factor VIII injections have a high incidence of HIV and HCV infection, with immunological aberration.
Keywords: Adult Factor VIII/THERAPEUTIC USE Hemophilia/*COMPLICATIONS/IMMUNOLOGY/THERAPY Hepatitis Antibodies/BLOOD Hepatitis B/*ETIOLOGY Hepatitis B Surface Antigens/BLOOD Hepatitis C/*ETIOLOGY Human HIV Infections/*ETIOLOGY HIV Seropositivity Male Middle Age JOURNAL ARTICLEKWDadultfactorviii/therapeuticusehemophilia/KWDcomplications/immunology/therapyhepatitisantibodies/bloodhepatitisb/KWDetiologyhepatitisbsurfaceantigens/bloodhepatitisc/KWDetiologyhumanhivinfections/KWDetiologyhivseropositivitymalemiddleagejournalarticle
931030
M93A0768

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .